Although the link between MET-dependence biomarkers and MET inhibitor response in HCC remains unclear, case reports suggest that HCC patients with MET amplification (METamp) may respond to MET-targeted therapies (Chen et al., 2021; Yan et al., 2023; Sang et al., 2023; Gu et al., 2023). Here, MET is linked to hepatocellular carcinoma.